Annovis Bio (ANVS) AI Stock Analysis

• Market Cap: $24.94M
• Dividend Yield: N/A
• Average Volume (3M): 270.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.52
• Revenue Growth: N/A
• EPS Growth: 68.75%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -2.00
• Shares Outstanding: 19,486,230
• 10 Day Avg. Volume: 268,932
• 30 Day Avg. Volume: 270,296
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.00
• Price Target Upside: 515.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Annovis Bio's overall stock score reflects significant financial challenges, with no revenue and heavy reliance on external funding. Technical indicators point to a bearish trend with potential further declines. Valuation concerns persist due to negative earnings. Corporate events present mixed influences: non-compliance with NYSE standards is a risk, while the Phase 3 Alzheimer's study could offer future growth potential.

Positive Factors

Drug Development

Annovis Bio, Inc. is set to conduct a pivotal Phase 3 study for Buntanetap in Alzheimer's Disease.

Market Valuation

The stock is viewed as significantly undervalued from a longer-term perspective, due to the high unmet need in Alzheimer's disease and the large potential market.

Regulatory Approvals

The FDA granted clearance to Annovis Bio to proceed with pivotal Phase 3 studies of its lead candidate buntanetap.

Negative Factors

Financing Challenges

Successfully navigating through funding needs remains very important to execute on its plans.

Market Conditions

Broad market headwinds continue including challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.

Stock Price Target

Factoring in dilution from the financing lowers the 12-month price target to $8, from $25.

Annovis Bio Business Overview & Revenue Model

Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

How the Company Makes Money

Annovis Bio generates revenue primarily through the development and potential commercialization of its therapeutic candidates. The company's revenue model is centered around advancing its drug candidates through clinical trials and eventually receiving regulatory approval for commercialization. Once a drug is approved, Annovis Bio may earn money through direct sales, licensing agreements, or partnerships with larger pharmaceutical companies for distribution and marketing. Additionally, the company may also receive funding from grants or collaborative research agreements with other institutions. However, as a clinical-stage company, Annovis Bio may not currently have significant revenue streams from commercialized products.

Annovis Bio Financial Statement Overview

Summary

Annovis Bio's financial statements reveal a company in the research phase typical of biotechnology firms, with no revenue and significant net losses. The balance sheet is bolstered by no debt, but negative equity poses risks. Cash flow analysis shows a heavy reliance on financing to support operations. The financial outlook is challenging without revenue generation or product commercialization.

Income Statement

Annovis Bio has reported zero revenue consistently since 2019, which is a significant concern for sustainability. The company has faced increasing net losses, with the latest annual report showing a net loss of approximately $24.59 billion. The lack of revenue and growing losses reflect poor financial health from an income perspective, typical for early-stage biotechnology firms focusing on R&D without a commercialized product.

Balance Sheet

The balance sheet shows that Annovis Bio has no debt, which is a positive sign. However, the company has a negative equity at times and fluctuating stockholders' equity, indicating financial instability. The equity ratio has been erratic, and the lack of tangible revenue-generating assets further complicates its financial stability.

Cash Flow

Operating cash flows have been consistently negative, reflecting the company's ongoing investments in operations without incoming cash flow from sales. While financing activities have provided some relief, the overall cash flow situation highlights a dependency on external funding to sustain operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00
	EBIT
0.00	-45.04M	-25.51M	-14.54M	-6.64M
	EBITDA
0.00	-45.04M	0.00	0.00	0.00
	Net Income Common Stockholders
-24.59B	-56.20M	-25.15M	-14.44M	-4.26M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.55B	5.75M	28.38M	45.69M	8.07M
	Total Assets
13.93B	10.21M	36.02M	46.00M	8.12M
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
-10.55M	-5.75M	-28.38M	-45.69M	-8.07M
	Total Liabilities
4.62B	17.96M	7.70M	1.51M	578.38K
	Stockholders Equity
9.31B	-7.75M	28.32M	44.49M	7.54M
Cash Flow		Free Cash Flow
-21.89B	-39.97M	-17.31M	-9.13M	-3.97M
	Operating Cash Flow
-21.89B	-39.97M	-17.31M	-9.13M	-3.97M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
26.69B	17.34M	4.61K	46.74M	12.04M

Annovis Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 1.3 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 2.01, and below the 200-day MA of 6.38, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 31.17 is Neutral, neither overbought nor oversold. The STOCH value of 8.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.

Annovis Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACAD	76 Outperform	$2.50B	10.38	38.89%	―	31.85%	―
BIIB	65 Neutral	$16.60B	10.30	10.36%	―	-1.60%	39.71%
AXSM	51 Neutral	$4.96B	―	-231.63%	―	42.53%	-15.29%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
PRTA	47 Neutral	$521.58M	―	-23.34%	―	47.92%	17.84%
SAVA	42 Neutral	$57.49M	―	-17.19%	―	―	81.00%
ANVS	38 Underperform	$24.94M	―	-3159.09%	―	―	68.75%

Annovis Bio Corporate Events

Annovis Bio Faces NYSE Non-Compliance Notice

On March 26, 2025, Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE) indicating non-compliance with the NYSE’s continued listing standards due to its average market capitalization and stockholders’ equity falling below $50 million. The company plans to submit a compliance plan within 45 days, which the NYSE will review to determine if Annovis can meet the standards within an 18-month period. The notice does not affect the company’s business operations or its reporting obligations, and its stock will continue to be traded with a ‘.BC’ designation until compliance is regained.

Annovis Bio Launches Phase 3 Alzheimer’s Study

On February 5, 2025, Annovis Bio Inc. announced the commencement of its pivotal Phase 3 study for the drug buntanetap in early Alzheimer’s disease, marking a significant step toward market approval. The study, which follows promising results from previous trials, is designed to assess both symptomatic and potential disease-modifying effects over an 18-month period and involves over 750 participants across the United States.